Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Payables (2019 - 2025)

Historic Payables for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $3.6 million.

  • Biodesix's Payables rose 4138.74% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 4138.74%. This contributed to the annual value of $2.2 million for FY2024, which is 2567.11% down from last year.
  • As of Q3 2025, Biodesix's Payables stood at $3.6 million, which was up 4138.74% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Payables ranged from a high of $16.4 million in Q3 2022 and a low of $1.6 million during Q1 2023
  • Moreover, its 5-year median value for Payables was $3.0 million (2023), whereas its average is $4.2 million.
  • In the last 5 years, Biodesix's Payables plummeted by 9461.53% in 2021 and then surged by 91444.44% in 2022.
  • Quarter analysis of 5 years shows Biodesix's Payables stood at $1.7 million in 2021, then rose by 3.15% to $1.7 million in 2022, then skyrocketed by 71.86% to $3.0 million in 2023, then fell by 25.67% to $2.2 million in 2024, then skyrocketed by 63.79% to $3.6 million in 2025.
  • Its Payables stands at $3.6 million for Q3 2025, versus $3.0 million for Q2 2025 and $2.9 million for Q1 2025.